The former Israeli army general commands a $15-billion-a-year drug powerhouse that makes generic knockoffs faster and in larger quantities -- some 8 billion pills a year -- than its competitors. The Israel-based company now accounts for 22% of all generic-drug sales in the U.S. and has been steadily adding to its portfolio, including a pending deal for Merck's Theramex unit. One of Teva's biggest sellers happens to be a proprietary drug it developed on its own: Copaxone, used to treat multiple sclerosis.
NEXT: 21. Wang Chuanfu